SOUTH ORANGE, NJ, April 24, 2019 – Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance liquid purification filters for both medical device and commercial markets, today announced that Daron Evans, CEO and Andy Astor, CFO will be presenting at the Taglich Brothers 16th Annual Investment Conference on Tuesday, April 30th at 9:30 AM ET in New York City.
The presentation will be webcast live with slides and can be accessed via the following link: https://www.webcaster4.com/Webcast/Page/2049/30171. The presentation will also be available on demand, after the conference.
Nephros is a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets. Nephros ultrafilters are primarily used in hospitals and medical clinics for added protection in retaining bacteria (e.g., Legionella, Pseudomonas) and viruses from water, providing barriers that assist in improving infection control in showers, sinks, and ice machines. Additionally, Nephros ultrafilters are used by dialysis centers for assisting in the added removal of endotoxins and other biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and patients.
Nephros Lead filters, including AETHER™ brand filters, improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Nephros and AETHER™ products are used in the health care, food service, hospitality, and convenience store markets.
For more information about Nephros, please visit the company’s website at www.nephros.com.
About Taglich Brothers
Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
Investor Relations Contact :